Garton & Associates Financial Advisors’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Garton & Associates Financial Advisors’s Portfolio CRXT Stock Details CRXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,354	Closed	–	–	743
2025 Q4	$0	Buy	+25,354	New	–	﹤0.01%	1179

Garton & Associates Financial Advisors's CRXT Position: Q1 2026 in Review

Garton & Associates Financial Advisors sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q1 2026, closing a stake of 25,354 shares.

Garton & Associates Financial Advisors first reported a position in CRXT in Q4 2025 and held it in 1 quarter. The position peaked at $0 in Q4 2025. 0 funds tracked by Wall St. Rank hold CRXT as of Q1 2026.

Garton & Associates Financial Advisors reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
Garton & Associates Financial Advisors sold 25,354 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q1 2026.
Garton & Associates Financial Advisors first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q4 2025 and held it in 1 quarter.
Garton & Associates Financial Advisors's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $0 in Q4 2025.
0 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q1 2026.

Based on Garton & Associates Financial Advisors's 13F filing for Q1 2026, filed 11 May 2026.